ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company working to develop therapies that enhance the immune system of patients, instead of weakening it. Since its inception in 2014 ...

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.